Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...
Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.
Bullish option flow detected in Gilead (GILD) with 14,401 calls trading, 4x expected, and implied vol increasing over 4 points to 27.50%.
Zacks.com on MSN17h
Cognizant Set to Report Q4 Earnings: What's in Store for the Stock?Cognizant Technology Solutions CTSH is scheduled to report its fourth-quarter 2024 results on Feb. 05. The Zacks Consensus ...
In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price ...
Hosted on MSN22h
Gilead Sciences Stock: Is Wall Street Bullish or Bearish?With a market cap of $121,1 billion, Gilead Sciences, Inc. (GILD) is a leading biopharmaceutical company specializing in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback